- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The company has announced it will advance its evaluation of BXCL701 into multiple advanced solid tumors in its Phase 2 clinical trial.
BioXcel Therapeutics (NASDAQ:BTAI) has announced that it will advance its clinical evaluation of BXCL801 into multiple advanced solid tumors.
As quoted in the press release:
BXCL701 is an orally active, systemic innate immunity activator with dual mechanisms of action.
“This new study allows us to accelerate the evaluation of BXCL701 in combination with a checkpoint inhibitor in patients with a range of tumor types where checkpoint inhibitors are standard of care,” commented Vincent J. O’Neill, M.D., Senior Vice President and Chief Medical Officer of BTI. “We believe BXCL701 may have the potential to extend treatment responses to KEYTRUDA®, a PD-1 inhibitor, when used together to treat advanced solid cancers. This trial expands on our studies of BXCL701 in prostate and pancreatic cancers as we explore its full potential.”
The open-label Phase 2 basket trial (NCT04171219) will take place at a leading cancer center in the U.S. The study is designed to evaluate the response rate of orally administered BXCL701, combined with Pembrolizumab (KEYTRUDA®) in patients with advanced solid cancers. If successful, the study would provide an option for patients who have failed or are refractory to checkpoint therapy. Outcome measures will include progression-free-survival, overall survival, and duration of response, as well as the safety of the combined treatment.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.